Gut Microbiota Modulation in Type 2 Diabetes Management

Type 2 diabetes is characterised by insufficient insulin action leading to chronic hyperglycaemia and metabolic complications worldwide. Research over the past decade has revealed that the gut microbiota—a diverse community of bacteria, archaea, viruses and fungi residing in the gastrointestinal tract—exerts profound influences on host glucose metabolism, inflammation and energy balance. Dysbiosis, or imbalanced microbial communities, is frequently observed in individuals with type 2 diabetes, accompanied by reduced diversity and altered proportions of key taxa. Interventions aimed at modulating the microbiota include dietary modification with prebiotic fibres, administration of probiotic strains, targeted delivery of polyphenols and development of gut-focused pharmacological agents. These approaches seek to enhance production of beneficial metabolites such as short-chain fatty acids, restore epithelial barrier integrity, alter bile-acid signalling, and attenuate low-grade inflammation. Translational studies in animal models and human clinical trials have demonstrated improvements in insulin sensitivity, lipid profiles and glucose tolerance, heralding microbiota-centred therapies as a complementary strategy in global diabetes management.

Research from Nature Portfolio

Recent studies have dissected how microbial carbohydrate metabolism contributes to insulin resistance. By integrating faecal metabolomics with metagenomics and host transcriptomics in human cohorts, researchers identified elevated levels of host-accessible monosaccharides in individuals with insulin resistance. Specific gut bacteria associated with either impaired or preserved insulin sensitivity were shown to differ in their carbohydrate-metabolising capacities, and transplantation of insulin-sensitivity-associated strains into mouse models improved metabolic parameters, suggesting new targets for intervention.

Investigations into natural polyphenols revealed that resveratrol intervention remodels the gut microbiota and alters the bile-acid pool, leading to inhibition of the farnesoid X receptor and reduced chylomicron secretion, thereby attenuating obesity-related phenotypes relevant to diabetes. In addition, a longitudinal multi-omics analysis of individuals at risk of type 2 diabetes demonstrated distinct host–microbe interaction networks in insulin-resistant versus insulin-sensitive participants. Early molecular signatures involving inflammatory markers and xenobiotic signalling were detected prior to clinical onset, underscoring the potential for predictive microbiota-based diagnostics.

Gut Microbiota Modulation in Type 2 Diabetes Management publication trend

The graph below shows the total number of articles in gut microbiota modulation in type 2 diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of microorganisms inhabiting the gastrointestinal tract that influences host metabolism and immunity.

Dysbiosis: An imbalance in the composition or function of the gut microbiota associated with disease states.

Insulin resistance: A reduced responsiveness of tissues to insulin, leading to impaired glucose uptake and elevated blood glucose levels.

Short-chain fatty acids (SCFAs): Metabolic products of microbial fermentation of dietary fibres that modulate host energy metabolism and immune responses.

Bile acids: Molecules synthesised from cholesterol that aid fat digestion and serve as signalling mediators via nuclear receptors.

Multi-omics: An integrative analysis combining genomics, transcriptomics, metabolomics and other molecular data to capture complex biological interactions.

References

1. Gut microbial carbohydrate metabolism contributes to insulin resistance. Nature (2023).
2. Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature (2019).
3. Glucomannan promotes Bacteroides ovatus to improve intestinal barrier function and ameliorate insulin resistance. iMeta (2024).
4. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio (2018).